^
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
inotuzumab ozogamicin Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 rearrangement
|
ALL
|
CRLF2 rearrangement
|
ALL
|
T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 rearrangement
|
ALL
|
CRLF2 rearrangement
|
ALL
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
inotuzumab ozogamicin Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
blinatumomab Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks (NewA1)
|
blinatumomab Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks - (New A1)
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
CD22 positive
|
B Acute Lymphoblastic Leukemia
|
CD22 positive
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
nelarabine Sensitive: A1 - Approval
|
nelarabine Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
dasatinib Sensitive: A1 - Approval
|
dasatinib Sensitive: A1 - Approval
|
CD19 positive
|
ALL
|
CD19 positive
|
ALL
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
mercaptopurine Sensitive: A1 - Approval
|
mercaptopurine Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
vincristine liposomal Sensitive: A1 - Approval
|
vincristine liposomal Sensitive: A1 - Approval
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
recombinant Erwinia asparaginase Sensitive: A1 - Approval
|
recombinant Erwinia asparaginase Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
pegaspargase Sensitive: A1 - Approval
|
pegaspargase Sensitive: A1 - Approval
|
CD20 positive
|
Childhood B Acute Lymphoblastic Leukemia
|
CD20 positive
|
Childhood B Acute Lymphoblastic Leukemia
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317I
|
ALL
|
BCR-ABL1 F317I
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
PDGFRA fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
PDGFRA fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
ABL2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
ABL2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
FGFR fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
FGFR fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
IL7R mutation
|
Childhood B Acute Lymphoblastic Leukemia
|
IL7R mutation
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
SH2B3 alteration
|
Childhood B Acute Lymphoblastic Leukemia
|
SH2B3 alteration
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
CRLF2 rearrangement + JAK2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
CRLF2 rearrangement + JAK2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
EPOR rearrangement
|
Childhood B Acute Lymphoblastic Leukemia
|
EPOR rearrangement
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
bosutinib Sensitive: A2 - Guideline
|
bosutinib Sensitive: A2 - Guideline
|
BCR-ABL1 E255V
|
ALL
|
BCR-ABL1 E255V
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
CALGB 10403 Sensitive: A2 - Guideline
|
CALGB 10403 Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
imatinib Sensitive: A2 - Guideline
|
imatinib Sensitive: A2 - Guideline
|
ABL1 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
ABL1 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
JAK2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
JAK2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
prednisone + vincristine Sensitive: A2 - Guideline
|
prednisone + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
ifosfamide + etoposide oral + mitoxantrone Sensitive: A2 - Guideline
|
ifosfamide + etoposide oral + mitoxantrone Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
cytarabine + methotrexate Sensitive: A2 - Guideline
|
cytarabine + methotrexate Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
clofarabine Sensitive: A2 - Guideline
|
clofarabine Sensitive: A2 - Guideline
|
PDGFRB fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
PDGFRB fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
inotuzumab ozogamicin Sensitive: A2 - Guideline
|
inotuzumab ozogamicin Sensitive: A2 - Guideline
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A2 - Guideline
|
tisagenlecleucel-T Sensitive: A2 - Guideline
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline
|
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
vincristine + mitoxantrone + dexamethasone + pegaspargase Sensitive: A2 - Guideline
|
vincristine + mitoxantrone + dexamethasone + pegaspargase Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
imatinib Sensitive: A2 - Guideline
|
imatinib Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
bortezomib Sensitive: A2 - Guideline
|
bortezomib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A2 - Guideline
|
blinatumomab Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
BCR-ABL1 G250E
|
ALL
|
BCR-ABL1 G250E
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
inotuzumab ozogamicin Sensitive: A2 - Guideline
|
inotuzumab ozogamicin Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline
|
blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline
|
ABL1 T315I
|
ALL
|
ABL1 T315I
|
ALL
|
ponatinib Sensitive: A2 - Guideline
|
ponatinib Sensitive: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 F359I
|
ALL
|
BCR-ABL1 F359I
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F359C
|
ALL
|
BCR-ABL1 F359C
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F359V
|
ALL
|
BCR-ABL1 F359V
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 E255K
|
ALL
|
BCR-ABL1 E255K
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 Y253H
|
ALL
|
BCR-ABL1 Y253H
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F317C
|
ALL
|
BCR-ABL1 F317C
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317V
|
ALL
|
BCR-ABL1 F317V
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 T315A
|
ALL
|
BCR-ABL1 T315A
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 G250E
|
ALL
|
BCR-ABL1 G250E
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
CD20 positive
|
ALL
|
CD20 positive
|
ALL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
COG AALL0232 Sensitive: A2 - Guideline
|
COG AALL0232 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
MRC UKALLXII/ECOG2993 Sensitive: A2 - Guideline
|
MRC UKALLXII / ECOG2993 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
Linker 4-drug Sensitive: A2 - Guideline
|
Linker 4-drug Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
CALGB 8811 Larson Sensitive: A2 - Guideline
|
CALGB 8811 Larson Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
USC/MSKCC ALL Sensitive: A2 - Guideline
|
USC / MSKCC ALL Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
PETHEMA ALL-96 Sensitive: A2 - Guideline
|
PETHEMA ALL-96 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
GRAALL-2005 Sensitive: A2 - Guideline
|
GRAALL-2005 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
DFCI ALL Sensitive: A2 - Guideline
|
DFCI ALL Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
COG AALL0434 Sensitive: A2 - Guideline
|
COG AALL0434 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
prednisone + vincristine + daunorubicin + pegaspargase Sensitive: A2 - Guideline
|
prednisone + vincristine + daunorubicin + pegaspargase Sensitive: A2 - Guideline
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
prednisone + vincristine + daunorubicin + nelarabine + pegaspargase Sensitive: A2 - Guideline
|
prednisone + vincristine + daunorubicin + nelarabine + pegaspargase Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
bosutinib Sensitive: A2 - Guideline
|
bosutinib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
ponatinib Sensitive: A2 - Guideline
|
ponatinib Sensitive: A2 - Guideline
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
vincristine liposomal Sensitive: A2 - Guideline
|
vincristine liposomal Sensitive: A2 - Guideline
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
FLAG-IDA Sensitive: A2 - Guideline
|
FLAG-IDA Sensitive: A2 - Guideline
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
